Jun 06, 2019 / 02:30PM GMT
Biren N. Amin - Jefferies LLC, Research Division - MD and Senior Equity Research Analyst
Okay. Let's get started. My name is Biren Amin. I'm one of the biotech analysts here at Jefferies. I'd like to welcome our next company. We have Neurocrine Biosciences, their CEO, Kevin Gorman; CFO, Matt Abernethy. This is going to be a fireside chat.
So I guess, Matt, do you want to -- before we get started with Q&A, I don't know if you want to read, I guess -- or talk about forward-looking statements just so we cover that aspect.
Matthew C. Abernethy - Neurocrine Biosciences, Inc. - CFO
Yes. Kevin can kick this off.
Kevin C. Gorman - Neurocrine Biosciences, Inc. - CEO & Director
Yes. So we will be making forward-looking statements, so I direct you to our recent SEC filings for all the risks associated with the industry and with our company.
Questions and Answers:
Biren N. Amin - Jefferies LLC, Research Division - MD and Senior Equity Research AnalystGreat. So
Trustpilot
